Introduction
Drug delivery nanocarriers can be extremely advantageous to administer insoluble, sensitive or multi-components drugs by protecting the encapsulated therapeutic molecules from clearance, inactivation or degradation, as well as by reducing potential toxicity, increasing blood circulation time or tissue specificity. [1] [2] [3] [4] [5] Poly(lactic-co-glycolic acid) (PLGA) has demonstrated optimal properties for the encapsulation of a large variety of therapeutic agents and it is extensively employed in nanomedicine. 6, 7 Moreover, PLGA-based nanocarriers have been used as drug delivery systems to administer proteins, 8, 9 DNA 10 and anticancer drugs among others. 1, 11, 12 . Nonetheless, despite their compositional similarities, any novel PLGA-based drug delivery system will require of a thorough evaluation to address potential toxicity issues and study the pharmacokinetics and the pharmacodynamics of each specific carrier. Such preclinical in vitro and in vivo studies, comprising multiple biological characterization phases, could be expedited by endowing the carrier with complementary imaging capacities. For instance, in vitro cellular uptake can be easily imaged with fluorescence 13, 14 while radioimaging 15, 16 or near infrared (NIR) imaging 1, 17 are well suited for in vivo biodistribution studies. However, simultaneous incorporation of all these imaging probes into a single nanocarrier unnecessarily increases the complexity of the system, potentially limiting translation to the clinics. Moreover, any additional component of the theranostic carrier will have an enormous impact in the manufacturing process, production cost and in complying with the medical regulations. In this sense, a drug delivery nanocarrier easily adaptable to incorporate one or several imaging moieties in a modular approach can be a smart strategy to guide the carrier preclinical development while guaranteeing that a simpler formula is manufactured for the final product. However, this strategy is suitable only when the inclusion or removal of the imaging probes do not affect the size, shape and main compositional traits of the final carrier. Furthermore, conventional approaches to physically blend imaging probes within the carrier can lead to incomplete conclusions or misinterpretations on the carrier's biodistribution. 18, 19 For example, loading two different molecules as probes into the same carrier led to opposite conclusions regarding the kinetics of brain-specific delivery. 19 A growing body of evidence suggests that new methods will be required to monitor nanocarriers' biodistribution avoiding interference of the imaging moieties with the encapsulated drug or leaching of the imaging probes. 19, 20 Here, we report on PLGA nanocapsules (NCs) as a multimodal theranostic platform for in vivo drug delivery. We describe the chemical synthetic routes to covalently label the PLGA with biocompatible small molecule fluorophores or radioligands. It follows by the fabrication of PLGA NCs integrating several moieties for their in vitro and in vivo imaging.
Specifically, superparamagnetic iron oxide nanoparticles (SPIONs) enabled magnetic resonance imaging (MRI), fluorescence imaging at different emitting wavelengths (blue and NIR) and 89 Zr-labeling enabled positron emission tomography (PET) imaging. We show that the morphology and size of PLGA NCs are not altered by either the incorporation or the removal of one of the several imaging probes. In all cases, the imaging moieties are chemically attached to the PLGA shell matrix as opposed to being entrapped in the core of the nanocapsule. [13] [14] [15] 17 This approach is advantageous to avoid interferences of the imaging moieties with the cargo in the core 21 . This is especially important for delicate payloads such as proteins, enzymes or microRNAs. For this, we have used bovine serum albumin (BSA) as a model protein to evaluate the protein loading capability.
Experimental Section
All reagents were purchased from Sigma Aldrich unless specified otherwise. The Ethics Committee of Animal Experimentation of the Vall d'Hebron Research Institute approved all experimental animal procedures (protocol number 70.18), which were performed in accordance with the Spanish legislation and the Directives of the European Union. Experiments performed at CIC biomaGUNE were approved by the Ethical Committee of the institution and by the corresponding authorities (Departamento de Promoción Económica, Turismo y Medio Rural, Diputación Foral de guipuzcoa; projects code PRO-AE-SS-059 and PRO-AE-SS-067).
Modification and functionalization of the commercial PLGA
Synthesis of -NH 2 terminated PLGA (PLGA-NH 2 ). In order to introduce a terminal amine group to PLGA, the carboxylic acid terminal group of PLGA (lactic:glycolic ratio 50:50, RG502H, Mw 12,000) was activated and reacted with ethylenediamine. The carboxylic groups were firstly activated with N,N'dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS). 0.025 mmol of PLGA was dissolved in 8 ml of dichloromethane (DCM), then 0.1 mmol of DCC in 1 mL of DCM and 0.1 mmol of NHS in 0.5 mL of acetone were added into the polymer solution under magnetic stirring. PLGA-NHS activation was achieved after 4 h at room temperature (RT). The coupling reaction was accomplished by adding an excess amount of ethylenediamine (0.15 mmol) in 1 mL of DCM to the solution and further stir for 2 h. The majority of the insoluble by-product, dicyclohexylurea, was removed by centrifuging the solution after reaction at 9391 rcf for 15 min at 4 °C and discarding the pellet. The supernatant was filtered (0.2 µm PTFE syringe filter) to remove any trace of insoluble byproduct. PLGA-NH 2 was precipitated by slowly pouring the supernatant into an excess amount of ethanol (10-fold), where the un-reacted NHS/DCC/ethylenediamine were separated from the PLGA-NH 2 due to their solubility in ethanol. Precipitated PLGA-NH 2 was redissolved in DCM and reprecipitated in ethanol twice for purification. The purified PLGA-NH 2 was dried under vacuum. Synthesis of fluorophore terminated PLGA using fluorescamine (PLGA-Fluram). Fluorescamine (Fluram) is a non-fluorescent compound that reacts with primary amines (R-NH 2 ) fast and near completely forming the fluorophore of fluram derivative which emits strong fluorescence at  em = 465 nm ( ex = 390 nm). 22 0.025 mmol of as synthesized PLGA-NH 2 and 0.075 mmol of fluram were mixed and dissolved in 4 mL of acetone and the reaction took place in dark room after 2 h at RT under magnetic stirring. Then the solution was slowly dropped into an excess amount of ethanol (10-fold) to precipitate the product PLGA-Fluram. The PLGA-Fluoram was collected by centrifugation, redissolved it in acetone and reprecipitated in ethanol twice for purification. The purified PLGA-Fluram was dried under vacuum. Synthesis of fluorophore terminated PLGA using Cy7.5 (PLGA-Cy7.5). NIR fluorophore Cyanine7.5 ( em = 808 nm,  ex = 788 nm) was introduced to the end of PLGA-NH 2 by forming an amide bond between PLGA terminal amine group and amine reactive Cy7.5 NHS ester (Lumiprobe GmbH, Hannover, Germany). 0.025 mmol of the as synthesized PLGA-NH 2 and 0.05 mmol of Cy7.5 NHS ester were mixed and dissolved in 4 mL of acetone and 0.05 mmol of Et 3 N were added as catalyst. The reaction took place in dark after 6 h at RT under magnetic stirring. Then the solution was slowly poured into an excess amount of ethanol (10-fold) to precipitate the PLGA-Cy7.5. Collected the product by centrifugation, redissolved it in acetone and precipitated in ethanol twice for purification. The purified PLGA-Cy7.5 was dried under vacuum. Synthesis of DFO terminated PLGA (PLGA-DFO). 89 Zr chelator deferoxamine (DFO) was introduced to the terminal amine of PLGA-NH 2 by forming a thiocarbamide bond between PLGA terminal amine group and amine reactive p-NCS-Bz-DFO (CheMatech, Dijon, FRANCE). 0.025 mmol of the, as synthesized, PLGA-NH 2 and 0.05 mmol of p-NCS-Bz-DFO ester were mixed and dissolved in 4 mL of DMSO and 0.05 mmol of Et 3 N were added as catalyst. The reaction was accomplished after 12 h at RT under magnetic stirring. Then the DMSO solution was mixed with 2-fold of DCM and slowly dropped into 10-fold of diethyl ether to precipitate the PLGA-DFO and unreacted p-NCS-Bz-DFO, that were collected by centrifugation at 9391 rcf for 10 min. The PLGA-DFO/p-NCS-Bz-DFO mixture pellet was dissolved in 1.5 mL of DCM and Please do not adjust margins Please do not adjust margins centrifuged at 13171 rcf for 60 min to remove the insoluble p-NCS-Bz-DFO. The supernatant was further filtered (0.2 m PTFE syringe filter) to remove the traces of p-NCS-Bz-DFO. Finally the PLGA-DFO was precipitated by slowly dropping the supernatant into 10-fold of diethyl ether, collected by centrifugation and dried under vacuum.
Synthesis of SPIONs coated with oleic acid (OA-SPIONs)
SPIONs were synthesized through a microwave assisted thermal decomposition in a microwave synthesizer (Discover SP, CEM Corporation) at a frequency of 2.45 GHz and 300W of power and then coated by oleic acid (OA). 23 Briefly, the process to obtain homogeneous OA-SPIONs with an average diameter of 9 nm was as follows. In a microwave reaction glass tube 3.5 mmol of iron precursor Fe(acac) 3 was dissolved in 4.5 mL of benzyl alcohol. The tube was closed and the microwave irradiation took place with the power set at 300 W. The solution was kept at 60 °C for 5 min to fully dissolve the precursor and subsequently heated to 210 °C and kept at this temperature for 30 min then cooled down to room temperature. After the reaction, a black colored dispersion formed which suggested the formation of magnetic material. Then 3.17 mmol of oleic acid in 4 mL of toluene was added to the product dispersion and sonicated for 1 h. Then 5-fold of acetone was added followed by centrifugation to sediment the product pellet. The pellet was redispersed in 4 mL of toluene and transferred into a glass vial, a magnet was attached on the wall and after 5 s the suspension containing SPIONs with smaller size and lower magnetization was discarded. Then the pellet was redispersed in 6 mL of DCM followed by centrifugation at 1075 rcf for 5 min to sediment the unstable big particles. The OA-SPIONs of 9 nm stable in DCM were precipitated by adding 5-fold of acetone and centrifugation. The final black product was dried under vacuum and redispersed in DCM at the concentration required for use.
Fabrication of PLGA-based NCs and encapsulation of BSA
BSA encapsulated PLGA-based NC were prepared by the double emulsion solvent evaporation method. Briefly, 50 μL of inner aqueous phase (W 1 ) containing BSA (30 mg mL -1 ) was emulsified in 500 μL of DCM organic phase (O) composed of 50 mg of different proportions of PLGA/functional PLGA and a certain amount of OA-SPIONs by sonication at 200 W for 28 s (VC505, SONICS & MATERIALS, INC., USA) to form the first emulsion (W 1 /O). Then 2 ml of external aqueous phase (W 2 ) with PVA (20 mg mL -1 ) was added and the second emulsion (W 1 /O/W 2 ) was formed by sonication for an additional 28 s. The temperature during the whole emulsion process was kept at 4 °C by using an ice bath. The resulting double emulsion was poured into 50 mL of MilliQ water and mechanically stirred at RT for 2 h to allow complete evaporation of the organic solvent and formation of NCs. Finally, the NCs pellet was obtained by centrifugation at 9391 rcf for 15 min and washed three times with 50 mL of MilliQ water and then lyophilized in 6 mL of trehalose (2 mg mL -1 ) aqueous solution. The asobtained powder was stored at 4 °C with desiccant silica gel.
Physicochemical characterization of the polymers, SPIONs and PLGA-NC
ATR-FTIR, UV/Vis, TG, DLS. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) characterization of the polymers was performed on a Bruker Vertex 70 FTIR spectrometer with a Pike Miracle Single-Bounce diamond crystal plate accessory at room temperature. FTIR spectra were recorded over a wavelength range of 4000-500 cm -1 with a resolution of 4 cm -1 . Ultraviolet-visible infrared (UV/Vis) spectra of the fluorescent polymers were recorded on a Varian Cary-5000 UV/Vis spectrophotometer using a quartz cuvette with an optical path of 1 cm. Thermogravimetric (TG) analysis of oleic acid coated SPIONs was carried out on a SETSYS Evolution TGA (Setaram) from room temperature to 800 °C at a heating rate of 10 °C min -1 and a dynamic dry air flow. Dynamic light scattering (DLS) (Malvern Zetasizer) measurement of the hydrodynamic diameter and size distribution of NCs by intensity was performed by redispersing 0.5 mg of lyophilized powder into 1 mL of MilliQ water. Electron microscopies. Field emitting scanning electron microscope (SEM, FEI Quanta 200 FEG) and transmission electron microscope (TEM, JEOL JEM-1210) were used to study the morphologies of SPIONs and NCs. For the SEM sample preparation of NCs, 0.5 mg of lyophilized powder was redispersed into 1 mL of MilliQ water and centrifuged at 4000 rpm for 10 min. Then the supernatant was discarded to remove the trehalose and 1 mL of fresh water was added, the pellet of NCs was redispersed in water with ultrasound. Finally, 6L of the slightly turbid suspension was deposited onto a small slice of silicon wafer stuck on top of a carbon layer and dried at room temperature overnight. The sample was sputtered with Au-Pd (Emitech K550 Sputter Coater, 20 mA for 2 min). TEM samples were prepared by placing and drying one drop of the corresponding NCs or SPIONs dispersion on a copper grid at room temperature. SQUID. Superconductive quantum interference device (SQUID, Quantum Design MPMS5XL) was used to measure the magnetization of NCs and SPIONs and calculate the experimental SPIONs loading (wt% SPIONs ) and EE% SPIONs of NCs. A gelatin capsule filled with about 7 mg of samples topr with some cotton wool was inserted into the SQUID magnetometer sample holder and the hysteresis loop was measured from -50 kOe to 50 kOe at 5 K. The remnant magnetization of the magnetic NCs (M R , NCs , emu g -1 ) and of SPIONs (M R , SPIONs , emu g -1 ) at 5 K was used to calculate wt% SPIONs and EE% SPIONs as follows:
Fluorescence properties. Fluorescence spectra of the polymer PLGA-Fluram were acquired on PerkinElmer LS45 spectrofluorometer. Both the excitation and emission-slit widths were set at 10 nm. The quantum yield of the polymer was measured by the Williams' method 24 shown in Figure S3a . The molar extinction coefficient (ε, mol -1 L cm -1 ) of PLGA-Fluram was calculated according to the Beer-Lambert law, A = εCL. Here C and L are the concentration (mol/L) and length (cm) of the dye solution in a UV/Vis cuvette respectively. The brightness and photostability are two important intrinsic photophysical properties of fluorescent materials. The brightness intensity of PLGA-Fluram can be calculated by the extinction coefficient times the quantum yield. Photostability was measured by continuously illuminating polymer solution with excitation light at 390 nm and measuring the resulting emission at 483 nm for 3 h. Photostability of rhodamine B as a reference was tested with its maximum excitation at 540 nm and maximum emission at 625 nm for the same 3 h in aqueous solution. Fluorescence signals of different concentrations of PLGA-Fluram NC in saline were quantified in a 96-well by a microplate reader. The NCs were excited at the maximal excitation wavelength and the fluorescence signal was collected at the maximal emission wavelength.
In vitro and in vivo MRI of the NC.SPIONs
In vitro agarose phantoms of NCs were prepared by filling a series of glass microtubes with solutions of 0.63% agarose in water (Conda, Madrid), into which different amounts of NCs were admixed. The corresponding iron doses (mmol L -1 ) were calculated according to the wt% of SPIONs in each sample. T2 weighted images (T2WI) of the phantoms were acquired at 7 T in a 70/30 Bruker USR Biospec system (Bruker GmbH, Ettlingen) as follows: multi-slice multi-echo (MSME) sequence with echo time (TE) = 8 ms, repetition time (TR) = 2600 ms, average N = 2, matrix size = 160 × 160, field of view (FOV) = 24×24 mm, 14 slices of 1 mm thickness, spectrometer bandwidth (BW) of 474 Hz/pixel. Quantitative T2 values were obtained from handdrawn regions of interest (ROIs) by using curve fitting in the Image Sequence Analysis (ISA) Tool (ParaVision v.5.1). Balb/c female mice (16-17 weeks of age, n=2) were anesthetized with isoflurane (IsoFlo; Abbott Laboratories). T2WI were acquired pre-and 15-20 min post-administration of NCs (1.6 mg in 150 μL of saline through tail vein) using the following imaging parameters: MSME pulse sequence, 20 echo times with ΔTE=8 ms, TR= 2.6 s, N= 2 averages, matrix of 256x256 points covering a FOV of 25.6x25.6 mm 2 , giving a resolution of 100 µm in plane. 14 continuous slices of 1 mm thickness, and d BW= 75 kHz. Images were acquired with respiration gating by using a SAII Model 1030 monitoring & gating system, (Smal Animals Instruments, Stony Brook, NY, USA). Fat suppression was achieved by saturation pulse of 1050 Hz. T2 maps were constructed off-line using Image-J 1.50b (National Institutes of Health), data were fitted to a three parameter exponential decay equation (S=A+S0exp(-TE/T2), where S represents signal intensity, A, S0 and T2 are the fitting parameters), achieved by the "exponential decay with offset" equation of the fitting routine of ImageJ. Signal intensities in T2WI and T2 maps were quantified manually in selected ROIs using ImageJ. Afterwards mice were euthanized and organs preserved for histological analyses.
In vitro and in vivo NIRF imaging of the NC.PLGA-Cy7.5.
A series concentrations of NCs in 100 μL of saline (n=3) were prepared in a 96-well plate and imaged by Xenogen IVIS® Spectrum (λex/λem 710/820 nm). BALB/cAnNRj male mice (Janiver; 7-8 weeks of age, n=2) were deeply anesthetized with isoflurane and were injected via the tail vein with a NC at a dose of 1.6 mg in 200 μL of saline. The NIRF images were acquired on an Xenogen IVIS® Spectrum imaging system at 0.5 h, 1 h and 3 h post injection. At the end of the 3 h scan, the mice were euthanized to image signal intensity of the principal organs ex vivo together with blood and urine.
In vivo PET imaging of the 89 Zr labelled NC.PLGA-DFO.
The NC.PLGA-DFO were labelled with 89 Zr as follows: [ 89 Zr]ZrC 2 O 4 was produced in house following standard protocol. The as obtained 1500 µL of 1 M oxalic acid containing 89 Zr (8.2 mCi, 303.4 MBq) were neutralized with 2 M sodium carbonate (pH = 7.2) and the volume was adjusted to 3.5 mL with 0.5 M HEPES buffer. Six aliquots (1.6 mg each) of the lyophilized particles were dispersed in 50 µL MQ-water, 450 µL of the freshly prepared 89 Zr-solution was added to each and well mixed by sonication. After incubation over night at room temperature the particles were purified by centrifugation and washed two times with MQ-water followed by one wash with saline to remove all non-bound 89 Zr. The pellet of the last wash was dispersed in 120 µL of saline with an average calculated radiochemical yield of 70.1 % (decay-corrected). As the achieved samples were too high in activity, a one to one dilution with non-labelled particles was performed. The final injections (150 µL) were performed intravenously via tail vein of healthy female mice (Crl:CD1(ICR)) with an average injected activity of 161 µCi (6.0 MBq).
Imaging studies were conducted using positron emission tomography (PET) in combination with computerized tomography (CT), using the β-and X-cube micro system of Molecubes. Static whole body images (1 bed) were acquired in a 511 keV ± 30 % energetic window at 1h, 4h, 23h and 47h post injection (acquisition time 5 min for 1 h and 4 h, 20 min for 23 h and 47h). PET images were analyzed using PMOD image analysis software (PMOD Technologies Ltd, Zuerich, Switzerland).
Prussian Blue Stain
Liver samples from the mice submitted to PET were embedded in optimal cutting temperature (OCT) compound and kept at -80 o C until sliced in 8 µm sections with cryostat. After rehydration, sections were stained with Prussian Blue Iron Stain Kit (Polysciences Inc, USA) following manufacturers protocol except that potassium ferrocyanide:hydrochloric acid solution was kept for a total of 40 minutes and nuclear Fast Red for 1 minute. Images were acquired after dehydratation with a transmitted light microscope (Leica, Germany).
In vitro and in vivo toxicity evaluation of the NCs
Cell viability evaluation. The toxicity of the NCs on human brain endothelial cells (hCMEC/D3), and CD34+ endothelial cells 25, 26 was assessed by performing a viability assay with 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). For the hCMEC/D3 cells, 2×10 4 viable cells were distributed on a 24-well plate in 400 L Endothelial Growth Media (EGM2 from Lonza with 2% Fetal Bovine Serum and half the amount of the growth factors included in the kit) where at that 5×10 3 viable CD34+ endothelial cells were seeded on a 96well plate in complete media and incubated for 24 h at 37 °C and 5% of CO 2 . After this period, culture supernatants were substituted by basal cell culture media (serum-free medium) containing increasing doses of NCs at concentrations of 25 μg mL -1 , 50 μg mL -1 , 100 μg mL -1 (N=3, triplicate). The MTT assay was performed after 48 h of incubation, and absorbance of the resulting Formazan crystals diluted in DMSO was determined at 540 nm. Cell viability was referred as the percentage of viability compared with the control condition (without NC). In vivo safety. Body weights of mice were monitored periodically at 0 d, 1 d, 5 d, 8 d, 11 d and 13 d after i.v. injection of NCs in 150 µL of saline at a dose of 0.84 mg Fe kg -1 (n=5), where vehicle group received 150 µL of saline (n=5) and naïve group without treatment serving as control (n=3). At the end of 13 days blood samples were collected and liver/pancreas toxicity based on specific enzyme levels in plasma were analysed in all groups: Alanine Aminotransferase (ALT), Alkaline phosphatase (ALK), Aspartate Aminotransferase (AST) and α-amylase using a clinical chemistry analyser Olympus AU5800.
BSA loading content
The albumin content was determined directly using the CBQCA protein assay kit (Invitrogen™ ref. C6667), which determines the protein concentration based on the production of fluorescent products measurable at λ ex/ λ em = 450 nm/550 nm via non-covalent interaction between CBQCA and primary aliphatic amines of proteins. This highly sensitive fluorescencebased method showed compatibility with DMSO, SPIONs, detergents and other substances which interfere with many common used protein determination methods. Lyophilized NCs encapsulating albumin as well as empty NCs as control were fully dissolved in DMSO at 100 mg mL -1 . The protein contents in the NCs lysates were measured and calculated based on the difference in fluorescence with control and a calibration curve drawn with standard albumin solutions, the protein contents in the BSA solutions used for encapsulation were also measured. All determinations were performed in duplicate for each NCs batch. The experimental BSA loading content was expressed as μg of BSA per mg of NCs (μg mg -1 ). The encapsulation efficiency (EE%) was calculated as follows: Chemical modification of the PLGA with functional moieties Figure 2 shows the schematic representation for terminal modifications and functionalization of the PLGA. Firstly, the carboxylic acid end group of PLGA was activated with DCC and NHS to conjugate ethylenediamine and form PLGA-NH 2 , bearing a free primary amine group in the PLGA end ( Figure  2a ). An excess amount of ethylenediamine (6:1 ethylenediamine:PLGA mole ratio) was used to suppress the coupling reaction of PLGA-PLGA that could occur by the homofunctional crosslinker ethylenediamine. Subsequently, the three functional moieties with amine-reactive groups (Fluram, Cy7.5, DFO) could be respectively integrated at the end of the PLGA molecule through coupling reactions (Figure 2b ). Further details are reported in the Experimental Section. ATR-FTIR spectra of the commercial PLGA-COOH and the PLGA-NH 2 product confirmed their similar chemical structure and the successful modification ( Figure S1 in Supplementary Information (SI)). Reaction efficiency of PLGA-COOH to PLGA-NH 2 was quantified by measuring the conjugated amount of fluram to the -NH 2 groups. The UV absorbance of the PLGA-NH 2 product (Mw 12000 g moL -1 ) in chloroform at 390 nm due to the conjugation of fluram was compared with a standard calibration curve constructed from different concentrations of ethylenediamine prepared in the same conditions ( Figure S2) . A reaction efficiency of 86% of PLGA-COOH to PLGA-NH 2 was estimated, which means that the molar fraction of pure PLGA-NH 2 in the product was 0.86.
Results and discussion
Fluram is a non-fluorescent compound that reacts with primary amines (R-NH 2 ) fast and almost quantitatively to form a fluorescent derivative, which emits strong fluorescence at around 480 nm when excited at 390 nm. 22 Conjugation of this compound to the -NH 2 end of PLGA for fluorescence application is very advantageous considering that neither free fluram itself nor its hydrolysis product show fluorescence. As shown in Figure 3a , characteristic absorption peak of the fluorophore at 390 nm occurred in the UV-Vis spectrum of the conjugation product PLGA-Fluram but this was not observed neither in PLGA-NH 2 nor in the Fluram. The disappearance of the 309 nm absorption band of Fluram in the PLGA-Fluram product indicates that the purification process removes the vast majority of free Fluram. Fluorescence of the obtained PLGA-Fluram was evaluated and the excitation and emission spectra are depicted in Figure 3b . Importantly, the fluorescence intensity of PLGA-Fluram decreased only slightly (<5%) after continuous UV excitation at the maximum excitation wavelength for 3 h, thus exhibiting a photostability just slightly lower (2%) than rhodamine-B, a widely used commercial fluorescent dye (Figure 3c ). Photostability of PLGA-Fluram using a confocal microscope configuration is also included in Figure S3b . The fluorescence intensity of NCs fabricated by PLGA-Fluram decreased only 13% after 10 min of continuous illumination at 10% of laser power (401 nW). Considering the laser power applied to observe stained cells is generally less than 10%, our fluorescent NCs would exhibit good photostability at in vitro conditions. Note that the calculated quantum yield of PLGA-Fluram (18%) ( Figure S3a ) is much higher than the values reported for fluorescent proteins such as green fluorescent protein (GFP) (7.3%) and its blue variants (7.9%), 27 and similar to other polymeric fluorescent materials such as poly(amido amine)s. 28, 29 Finally, the calculated fluorescent brightness of PLGA-Fluram (25056) is also much higher than that of other reported biodegradable photo-luminescent poly(lactide-co-glycolide) (BPLP-co-PLGA) (6550-19230) 30 and other frequently used small organic dyes such as Alexa Fluor 430 (8800) or DAPI (15, 660) . The fluorescence intensities of the fabricated NCs show linear dependency on the NCs concentration, and NCs can be clearly imaged with a fluorescence microscope (Figure 3d ). Although in this work we have focused on in vivo imaging modalities, the remarkable fluorescent properties shown here endow the PLGA-Fluram system with very interesting features for in vitro fluorescence tracking studies. Next, the NIR fluorophore Cy7.5 was introduced to the terminal amine of PLGA-NH 2 via an amide bond between PLGA terminal amine group and amine-reactive Cy7.5 NHS ester. The absorption band of Cy7.5 appeared in the UV-Vis spectrum of PLGA-Cy7.5 product, which confirmed the successful conjugation of Cy7.5 ( Figure S4a ). The amount of conjugated Cy7.5 in the PLGA-Cy7.5 product was quantified by comparing the fluorescence intensity of PLGA-Cy7.5 product with freeCy7.5 ( Figure S4b ) in DMSO. Pure PLGA-Cy7.5 with a molar fraction of 0.65 was estimated in the product and a conjugation efficiency of 76% of Cy7.5 NHS ester to PLGA-NH 2 was calculated considering the fraction of pure PLGA-NH 2 is 0.86.
For the radiolabelling functionalization the 89 Zr chelator DFO was introduced to the end of PLGA-NH 2 by forming a thiocarbamide bond between PLGA terminal amine group and the amine reactive -NCS group in the DFO derivative p-NCS-Bz-DFO. Compared to the IR spectrum of PLGA-NH 2 , some new bands corresponding to the DFO conjugate appear in the spectrum of PLGA-DFO, indicating the successful conjugation of DFO ( Figure S1 ). The amount of conjugated DFO in the PLGA-DFO product was quantified by measuring the amount of unreacted PLGA-NH 2 through the fluram method described above ( Figure S2c ). Pure PLGA-DFO with a molar fraction of 0.75 was estimated in the product, and a conjugation efficiency of 88% of p-NCS-Bz-DFO to PLGA-NH 2 was calculated considering the fraction of pure PLGA-NH 2 is 0.86.
Fabrication of PLGA NCs with selected combinations of imaging moieties
PLGA NCs with encapsulated BSA were prepared by a double emulsion solvent evaporation method. 31 Imaging moieties were incorporated into the PLGA shell by adding to the organic phase various proportions of functionalized PLGA as well as the oleic acid (OA) coated SPIONs (Table 1) . Compositional changes of the organic phase did not affect the encapsulation process, all types of NCs prepared shown mean hydrodynamic sizes within a diameter range of 250 -300 nm and a polydispersity index (PdI) < 0.2. As seen in the table 1 from NC-1 to NC-3, neither increasing the SPIONs size nor increasing two-fold its loading affected the mean size of the NCs compared to plain PLGA NCs (NC-0). Note that for the same loading of SPIONs, the magnetization of NC-2 is much higher than that of NC-1 given to the larger size of SPIONs for NC-2. Therefore optimal formulation regarding SPIONs (6 wt%, with 9nm nanoparticles) yields an average saturation magnetization value of 4.06 emu g -1 NCs which is more than four-fold larger than our previously reported value (0.90 emu g -1 ). 31 As it will Figure S5 ). **SPIONs loading and entrapment efficiency (EE%) was determined by SQUID measurements at 5K. ***The fraction of SPIONs in OA-SPIONs was determined by thermogravimetric analysis (TGA) and the magnetization is expressed as emu/g SPIONs ( Figure S6 ). be shown later, the increase of the magnetic moment of a NC resulting from using larger size SPIONs and increasing their load positively impact on the MRI signal intensity. 32 Furthermore, the size of NCs as well as the SPIONs encapsulation efficiency (EE%) were not affected when various Table 1 are not affected as well (data not shown). Figure 4 contains a representative scanning electron microscope (SEM) image of the NCs (NC-3) presenting homogeneous spherical morphologies. The inset is a dynamic light scattering (DLS) size distribution histogram of lyophilized NCs redispersed in water. In this case, the mean hydrodynamic diameter of the NCs is 276 nm with a polydispersity index (PdI) of 0.18 reflecting good redispersability of the NCs in water after the lyophilizing process. As mentioned, all types of NCs listed in Table 1 had the similar morphologies and sizes ( Figure  S7 ), which were considered to be suitable for intravenous administration. 33 The upper inset in Figure 4 shows a representative broken NC, exposing the hollow core, ideal for the loading of protein drugs. The transmission electron microscopy (TEM) image in the lower inset revealed the embedding and finely homogeneous distribution of the SPIONs within the polymeric matrix.
NCs magnetic properties, accumulation and biodistribution by MRI
The magnetic hysteresis loop at room temperature of lyophilized NC-3 is displayed in Figure 5a showing thesuperparamagnetic character of the NCs (lack of coercivity). The superparamagnetic behavior of the NCs after SPIONs encapsulation is important since in the absence of an external magnetic field, it ensures lack of interactions among NCs thus minimizing the risk of embolization for i.v. administration. Themagnetic retention of NCs is illustrated with the use of an external magnet. As seen in Figure 5b , the colloidal water suspension of 2 mg mL -1 of NC-3 forms a round pellet next to the magnet after 7 h. The solution becomes completely clear indicating that great majority of the NCs are retained by the magnet. Previous experiments using magnetic PLGA nanoparticles 34 or microparticles loaded with only 1 wt% iron oxide 35 already demonstrated magnetic retention in rodent brain or knees, indicating that our protein loaded magnetic NCs with a higher magnetic load (6 wt%, M S = 4 emu/g) may have still better characteristics to address magnetic targeting.
Phantom studies were conducted to confirm the MRI performance of the NCs. Phantoms from two batches (NC-2 and NC-3) with different SPIONs loading (3 wt% and 6 wt%; 9 nm diameter) at a series of concentrations were prepared (Figure 5c ). Spin-spin relaxation time (T 2 ) weighted color-coded MRI images clearly exhibit signal decay in a concentration dependent manner. Importantly, at the same concentration NC-3 with 6 wt% SPIONs showed higher T 2 signal decay rate than NC-2 with 3 wt% SPIONs indicating that NC-3 will be easier to track in vivo by MRI. Furthermore, the transverse relaxivity (r 2 ) value at 7 Tesla of NC-3 (336 mM -1 s -1 ) was higher, as expected, than that of NC-2 (278 mM -1 s -1 ) as seen in Figure  5d , indicating that the denser packing of SPIONs in a single NC of NC-3 endows the NCs with a larger magnetic moment and increases its efficiency as a spin-spin relaxation agent. 36 Compared with other clinically used SPIONs systems such as Feridex (98 mM -1 s -1 ) and Resovist (151 mM -1 s -1 ), 37 the much higher r 2 value in our final NC formula (6wt% SPIONs of 9 nm in diameter) is expected to be useful for in vivo MRI tracking of the NCs.
As the representative abdominal images show in Figure 6b , a much clearer increase of contrast of the liver was observed in both T2WI and T2 map after NCs administration, illustrating the fast accumulation of NCs in liver. Quantitative ROIs analysis in Figure 6c shows a 55% drop of signal intensity (SI) on T2W images and a 26% drop of T2 relaxation time in the liver, while negligible signal drop was observed in the kidney, which further demonstrate the large accumulation of NCs in this organ. To further confirm the presence of NCs in the tissue, Prussian blue staining on liver sections confirmed the presence of ferric iron (Figure 6d ) after the in vivo MRI.
Biodistribution of the NCs monitored by PET
With a ∼3 day half-life, 89 Zr-based PET imaging holds great potential as a useful tool for long-term monitoring of thedynamic biodistribution, biodegradation and clearance pathway of nanoparticles in vivo. 38 Our results showed that 89 Zr-labelling has a yield of about 70% for NC.PLGA-DFO (NC-5) after overnight incubation at room temperature at a concentration of 3 mg mL -1 . A DFO challenge study has been reported to demonstrate the radiostability of 89 Zrlabellednanoparticles. 39 In our study, the as-obtained NC.PLGA-DFO-89 Zr was suspended in 1 mM DFO aqueous solution and incubated at 37 ºC for 23 h. Then the NCs were separated by centrifugation and 100 % were still labelled, with no presence of 89 Zr-DFO in the supernatant, demonstrating a strong binding affinity of 89 Zr to the NC.PLGA-DFO. 89 Zr labelled NC.PLGA-SPIONs-DFO-89 Zr (NC-5) was then injected via tail vein with the same iron dosage as for the MRI study (1.68 mg Fe kg -1 ) to anesthetized mice. Static whole body PET-CT images were acquired at 1 h, 4 h, 23 h and 47 h p.i.. Dominant liver, spleen and lung uptake was observed ( Figure  7a ) and confirmed by the quantitative ROI analysis (Figure 7b ) within two days, which can be related to phagocytic cell uptake by the mononuclear phagocyte system, 1 as expected for i.v. injected PLGA nanoparticles of this size. 17 Interestingly, noticeable bladder accumulation (∼22 %ID cm -3 ) was observed at 1 h p.i., with a sharp decrease at 4 h p.i. (∼ 6 %ID cm -3 ) likely due to uncontrolled animals' urination between scans. The early stage activity in bladder could also be confirmed by continuous PET-CT acquisition ( Figure S8 ), which showed a linear increase of activity within 3h p.i.. It is hard to assign the activity in the urine to the detachment of free 89 Zr from the NCs, since detached free 89 Zr is a well-known osteophilic cation with a fast and retained uptake in bones, 38, 40 which is not detectable in our case. In Chen et al. study, 38 both free 89 Zroxalate or 89 Zr labelled SiO 2 nanoparticles, fast and sustained uptake of free/detached 89 Zr in bones and joints was observed from the first few hours up to three weeks, while the accumulation in bladder was negligible. We thus hypothesized that the erosion of the soft polymeric NCs had happened at early stage in the complex blood circulation environment. The detached 89 Zr-molecular fragments from the NCs, either by degradation of ester bonds in PLGA molecular chains or thiocarbamide bonds between PLGA and DFO or by mechanical force, with a size smaller than 15 nm 41 underwent renal clearance and observed in bladder. Additional experiments showed erosion of NCs clearly observed after in vitro incubation in mouse plasma at 37 °C for 24 h (Figure 7c ). Small holes appeared on the NCs while at the same conditions NCs incubated in saline did not show the same eroded surface (Figure 7d ). Considering the in vivo blood circulation setting, the erosion of PLGA NCs would be much faster as reported by Swider. 42 Not surprisingly, at late time points the concentration of radioactivity in the bladder decreases likely due to fast accumulation of the NCs in the liver/spleen.
NCs biodistribution monitored by Near Infrared Fluorescence (NIRF) imaging
To investigate the feasibility of the formulation NC.PLGA-Cy7.5 (NC-6) for in vivo NIRF imaging, in vitro fluorescent performance was firstly checked. In vitro fluorescence intensity of the NC-6 was linearly dependent on the concentrations of NCs, showing strong fluorescence and no quenching up to a high level of 1 mg mL -1 (Figure 8a ). Realtime whole-body imaging revealed a dominant abdominal distribution of the NCs with a total radiant efficiency (TRE) of ∼ 42.40 vs. control at 2 h p.i.. At the end of the observation, main organs including brain, heart, lung, liver, spleen, kidney, and bladder were collected. Figure 8c shows a representative ex vivo fluorescence picture of those organs and Figure 8d shows the quantified result of the biodistribution of the NCs. Dominant liver, spleen and lung accumulation was observed which was consistent with the data acquired with PET. Note that we did also see the bladder signal during the real-time imaging, which further demonstrated the erosion of NCs really happened at the early stage p.i., considering that the NIRF imaging is less sensitive than PET. The unobservable ex vivo bladder signal may resulted from the uncontrolled urination and urine sample collection.
From the above discussion, similar biodistribution of the NCs with different imaging probes for MRI/PET/NIRF was evidenced. That was expected since the only difference among the NCs for these three imaging modalities is the existence or not of small molecule 89 Zr-DFO or Cy7.5 at the end of PLGA molecular chain. As we have demonstrated, the imaging probes in the matrix of PLGA shell do not affect the size of the NCs, which is a key attribute influencing the biodistribution and pharmacokinetics of the nanocarriers. 17, 41, 43 Thus, the incorporation or removal of these small molecules in the shell does not affect the NCs' in vivo biodistribution and made-toorder capsules can be fabricated with the appropriate imaging probe needed for each specific in vivo and in vitro study. Moreover, simultaneous multimodal imaging is an option through custom-tuning the functional moieties in the capsules. Despite that bare (non-PEGylated) NCs were used here, the PLGA NCs can also be easily pegylated as shown for the NC-8 system (3 wt% PEG Mn 5000) and modify the NCs blood circulation time. Moreover, the magnetic functionality could be exploited for magnetic targeting in a selected organ or tissue.
NCs in vitro and in vivo safety
In vitro and in vivo safety studies of NC-3 (PLGA.SPIONs NCs) were conducted considering that this is the simplest therapeutic formulation for magnetically targeted delivery. We tested the effect of NC-3 on proliferation/viability of human endothelial cells since endothelial cells lining the blood vessels are the first NC target following their intravenous administration. Thus, human brain endothelial cells (hCMEC/D3), a cell line derived from brain microcirculation, and primary cultures of human CD34 + -derived endothelial cells were exposed to NC-3 and its cytotoxicity was evaluated by performing a MTT assay. As shown in Figure 9a , the cells did not exhibited decrease in viability after being exposed for 48 h to the NCs from 25 to 100 μg mL -1 , the differences of cell viability between groups were not significant (ANOVA > 0.05), thus our results suggest that the NCs are biocompatible for the studied range of concentrations and time. Thereafter, the systemic effect of NCs via i.v. administration was evaluated. Figure 9b shows that after injection of NCs, all animals maintained the body weight within normal values for two weeks (no differences between groups at the end of the experimental period), with no significant morbidity and no potential adverse effects. At the same time, blood samples tests to monitor potential liver and pancreatic toxicity showed that none of the biomarker enzymes were significantly different between groups and similar to those measured in non-treated mice (Figure 9c ; ANOVA > 0.05), suggesting a normal activity of these organs. All the above results reinforce the biosafety of this formulation of nanocarriers for future clinical translational practice.
Protein loading
The protein loading content was determined as 11.3 ± 1.0 µg BSA/mg NCs (1.13 wt%) with an encapsulation efficiency of 46.0 ± 1.4%, the average of six different batches measured. The protein loading of 1.13 wt% is much higher than the reported value (0.03 wt%) of vessel endothelial growth factor loaded PLGA NCs 31 and the EE% is comparable to the PLGA NCs loaded with neurotrophin-3 (47 ± 2%) or brain-derived neurotrophic factor (47 ± 7%). 8
Conclusions
By covalently bonding PLGA with small molecules of fluorophores and radioligands as well as by incorporating iron oxide nanoparticles we here propose chemical synthetic approaches to transform PLGA NCs into a sensitive, multimodal theranostic platform for drug delivery. We have shown that the size of PLGA NCs remained unaltered after incorporation or removal of one or several imaging moieties. We have proposed a modular approach for capsules with multimodal capacities to be used at several development phases and investigated by different imaging modalities including MRI, fluorescence at different emitting wavelengths (blue and NIR) or 89 Zr-labeling enabled positron emission tomography (PET) imaging. In all cases, the imaging moieties are chemically attached to the PLGA and with minimal interaction with the encapsulated drug thus avoiding leaching and interferences with the therapeutic agent.
The theranostic PLGA NCs show no toxicity in vitro nor in vivo. In this regard, the NCs did not affect the viability of two different human endothelial cells (brain endothelial cell and CD34 + derived endothelial cells) for concentration up to 100 g mL -1 . In vivo biosafety was shown based on the lack of morbidity of mice for 2 weeks after the systemic NCs administration and the fact that none of the biomarker enzymes monitored were significantly different between groups and similar to those measured in non-treated mice.
Finally, we have shown that the NCs can contain over 1% wt of protein in their core achieved at fabrication level. Interestingly, PLGA NC decorated with iron oxide nanoparticles can be exploited for magnetic retention or magnetic guiding and biodistribution could be modified by using PEG-PLGA NCs.
